Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology

The Path to Secondary Progressive MS

At a Glance

Secondary progressive MS is usually identified over time by a sustained increase in disability that is not explained by a relapse. There is no single test or date marking the transition, and progression, monitoring, and treatment vary from person to person.

The transition from Relapsing-Remitting Multiple Sclerosis (RRMS) to Secondary Progressive Multiple Sclerosis (SPMS) is rarely a single moment in time. Instead, it is a gradual shift where the nature of the disease changes from episodic attacks to a more constant, slow accumulation of disability [1][2]. This period is often marked by significant diagnostic uncertainty. You may feel that your symptoms are worsening while your clinical tests remain stable, or you may wait years for a formal change in your diagnosis [3]. This delay is not typically a sign of medical oversight; it is a reflection of the biological reality that SPMS is a continuum, not a sudden switch [4].

The Biological Shift

While RRMS and SPMS are parts of the same disease, they involve overlapping biological mechanisms.

  • RRMS (Peripheral Inflammation): In the relapsing phase, the blood-brain barrier (BBB)—the protective shield around your central nervous system—periodically breaks down. This allows immune cells from the rest of your body to rush into the brain and spinal cord, causing focal “attacks” or lesions [5].
  • SPMS (Compartmentalized Inflammation): In the progressive phase, inflammation often becomes compartmentalized, meaning it happens “behind closed doors” within the brain and spinal cord, often while the BBB is relatively intact [5]. This involves microglia (the brain’s resident immune cells) becoming chronically active, leading to ongoing tissue injury [6][7].
  • Neurodegeneration: Progressive disease is characterized by neurodegeneration, where nerve fibers (axons) are damaged by energy failure in the mitochondria and oxidative stress [8][9]. This can occur even if no new lesions are appearing on an MRI [10].

Why Diagnosis Takes Time

Clinicians often recognize SPMS retrospectively—looking back at months or years of data to confirm a trend [11]. There is currently no single blood test, MRI finding, or “biomarker” that can pinpoint the exact day the transition occurs [2][12].

Instead, doctors look for Progression Independent of Relapse Activity (PIRA). PIRA is a measurement concept describing a sustained worsening of disability that is not caused by a specific relapse [13][10]. To confirm SPMS, many experts use a standard called the Expanded Disability Status Scale (EDSS). One operational framework used by some clinicians looks for:

  1. Worsening of disability for at least 6 months without a relapse [12].
  2. An increase of 1.0 point on the EDSS if your previous score was 5.0 or lower, or 0.5 points if it was 5.5 or higher [12].
  3. Confirmation of this worsening 3 to 6 months later [12].

Note: This is one example of a framework, not a rigid rule. Diagnosis remains a clinical judgment based on repeated functional change and the exclusion of other causes.

Timeline and Expectations

The timeline for this transition varies widely. Historically, older population studies suggested that about half of people with RRMS might transition to SPMS within 15 to 20 years of their initial diagnosis, and up to two-thirds by 30 years [14][3]. However, these are historical estimates, not a predictable timetable for you. Modern disease-modifying therapies (DMTs) and updated diagnostic criteria appear to be changing this transition for many patients [15][16].

It is important to address two common fears:

  • Treatment does not stop: Transitioning to SPMS does not mean you have run out of options. While some drugs are specifically for relapsing MS, others are approved specifically for “active” SPMS (where relapses or new MRI lesions still occur) in many jurisdictions [NCT07840326].
  • Disability is not immediate: Moving into the progressive phase does not mean you will immediately require a wheelchair. The rate of progression is often very slow, and many people continue to work and remain mobile for decades after transitioning, though this requires individualized assessment [3][17].

Monitoring the Transition

Because the shift is subtle, your medical team may use “EDSS-plus” measures, which include more sensitive tests like walking speed (the Timed 25-Foot Walk) or hand dexterity (the Nine-Hole Peg Test) [18]. Cognitive changes, such as increased “brain fog” or difficulty processing information quickly, are also warning signs that your doctor will monitor alongside physical symptoms [19][20]. Managing other health issues—like sleep apnea, infections, or deconditioning—is vital during this time, as these can sometimes mimic disease progression [12].

Common questions in this guide

How is secondary progressive MS different from relapsing-remitting MS?
Relapsing-remitting MS is mainly marked by distinct attacks followed by periods of partial or complete recovery. Secondary progressive MS involves a more continuous accumulation of disability over time, although relapses and new MRI lesions can still occur in some people.
Is there a single test that confirms the transition to SPMS?
No. Doctors usually make the diagnosis by reviewing changes in function and disability over time, considering relapses and MRI findings, and ruling out other causes that can worsen symptoms.
What does progression independent of relapse activity mean in MS?
Progression independent of relapse activity, or PIRA, means that disability has worsened gradually without a clear MS relapse causing the change. It is one concept clinicians use when assessing whether progressive disease may be developing.
Does an SPMS diagnosis mean my MS treatment will stop?
No. Treatment options may remain available, especially when SPMS is active, meaning relapses or new MRI lesions are still occurring. The best treatment plan depends on your disease activity, symptoms, health, and the medicines approved where you live.
Does transitioning to SPMS mean I will need a wheelchair soon?
No. The transition does not predict an immediate loss of mobility; progression rates vary widely and may be slow. Your neurologist can assess your individual walking ability, disability trend, and other health factors to discuss likely needs and supports.
How do doctors monitor possible progression to SPMS?
They may compare disability scores over several visits with walking, hand-dexterity, and cognitive assessments, as well as brain or spinal cord MRI results. They also look for problems such as sleep apnea, infection, or deconditioning that can temporarily worsen function or mimic progression.

Get notified when new evidence is published on secondary progressive multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.

    Boyko A, Therapontos C, Horakova D, et al.

    Multiple sclerosis and related disorders 2021; (50()):102778 doi:10.1016/j.msard.2021.102778.

    PMID: 33592384
  2. 2

    Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment.

    Adamczyk-Sowa M, Adamczyk B, Kułakowska A, et al.

    Neurologia i neurochirurgia polska 2020; (54(5)):384-398 doi:10.5603/PJNNS.a2020.0082.

    PMID: 33058113
  3. 3

    The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.

    Sharmin S, Roos I, Simpson-Yap S, et al.

    Brain : a journal of neurology 2023; (146(11)):4633-4644 doi:10.1093/brain/awad218.

    PMID: 37369086
  4. 4

    A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis.

    Kee R, Naughton M, McDonnell GV, et al.

    Biomedicines 2022; (10(10)) doi:10.3390/biomedicines10102604.

    PMID: 36289863
  5. 5

    Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.

    Lassmann H

    Frontiers in immunology 2018; (9()):3116 doi:10.3389/fimmu.2018.03116.

    PMID: 30687321
  6. 6

    Longitudinal accumulation of glial activation measured by TSPO-PET predicts later brain atrophy in multiple sclerosis.

    Nylund M, Lehto J, Matilainen M, et al.

    Journal of neuroinflammation 2025; (22(1)):200 doi:10.1186/s12974-025-03519-y.

    PMID: 40775641
  7. 7

    Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.

    Kamma E, Lasisi W, Libner C, et al.

    Journal of neuroinflammation 2022; (19(1)):45 doi:10.1186/s12974-022-02408-y.

    PMID: 35144628
  8. 8

    Progressive multiple sclerosis: from pathophysiology to therapeutic strategies.

    Faissner S, Plemel JR, Gold R, Yong VW

    Nature reviews. Drug discovery 2019; (18(12)):905-922 doi:10.1038/s41573-019-0035-2.

    PMID: 31399729
  9. 9

    Mitochondrial Dysfunction and Multiple Sclerosis.

    Barcelos IP, Troxell RM, Graves JS

    Biology 2019; (8(2)) doi:10.3390/biology8020037.

    PMID: 31083577
  10. 10

    Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity.

    Ransohoff RM

    Trends in immunology 2023; (44(4)):266-275 doi:10.1016/j.it.2023.02.002.

    PMID: 36868982
  11. 11

    Markers of secondary progression in multiple sclerosis.

    Bastos A, Soares M, Guimarães J

    Multiple sclerosis and related disorders 2024; (91()):105881 doi:10.1016/j.msard.2024.105881.

    PMID: 39277977
  12. 12

    Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteria.

    Ciron J, Gueguen A, Al Khedr A, et al.

    Revue neurologique 2022; (178(10)):1098-1104 doi:10.1016/j.neurol.2022.07.004.

    PMID: 36180289
  13. 13

    Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

    Müller J, Sharmin S, Lorscheider J, et al.

    JAMA neurology 2025; (82(6)):614-625 doi:10.1001/jamaneurol.2025.0495.

    PMID: 40227706
  14. 14

    A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.

    Inojosa H, Proschmann U, Akgün K, Ziemssen T

    Journal of neurology 2021; (268(4)):1210-1221 doi:10.1007/s00415-019-09489-5.

    PMID: 31363847
  15. 15

    Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.

    Tedeholm H, Piehl F, Lycke J, et al.

    Multiple sclerosis and related disorders 2022; (68()):104220 doi:10.1016/j.msard.2022.104220.

    PMID: 36242804
  16. 16

    The impact of changing diagnostic criteria on disability in a Brazilian multiple sclerosis cohort.

    Menezes FTL, Alencar JMD, Lopes AB, et al.

    Arquivos de neuro-psiquiatria 2025; (83(6)):1-9 doi:10.1055/s-0045-1809662.

    PMID: 40562370
  17. 17

    Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.

    Iaffaldano P, Lucisano G, Patti F, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2021; (27(3)):430-438 doi:10.1177/1352458520974366.

    PMID: 33210986
  18. 18

    The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.

    Cadavid D, Cohen JA, Freedman MS, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(1)):94-105 doi:10.1177/1352458516638941.

    PMID: 27003945
  19. 19

    The Faces of "Too Late"-A Surprisingly Progressive Cohort of "Stable" Relapsing Remitting Multiple Sclerosis Patients.

    Ciubotaru A, Grosu C, Alexa D, et al.

    Medicina (Kaunas, Lithuania) 2024; (60(9)) doi:10.3390/medicina60091401.

    PMID: 39336442
  20. 20

    Beyond relapse control: motor and cognitive subclinical progression in RRMS -a real-world longitudinal study of ocrelizumab and interferon beta.

    Todorović S, Vojinović S, Savić D, et al.

    Acta neurologica Belgica 2026; (126(4)):1259-1268 doi:10.1007/s13760-026-03063-3.

    PMID: 41975172

This page is for informational purposes only and does not constitute medical advice. It explains general patterns in the transition to SPMS; your neurologist or MS care team should interpret your symptoms, scans, and disability scores.

Guide contents secondary progressive multiple sclerosis
Research & Literature
02 Tracking the Transition